Mannitol Injection, Solution
Product Images NDC 0404-9905

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Mannitol (NDC 0404-9905). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Henry Schein, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula1.jpg (Formula1)

Water for Injection, USP is a chemical compound used for the preparation of various pharmaceutical drugs. Its chemical formula is not clearly mentioned in the given text.*

FDA Label Image

Image1.jpg (Image1)

This text describes the potential side effects of a medication. These side effects include hypersensitivity reactions such as cardiac arrest and anaphylaxis, renal failure, CNS toxicity, fluid and electrolyte imbalances, infusion site reactions, cardiac and respiratory disorders, gastrointestinal disorders, and general disorders such as thirst. These side effects are outlined in more detail within the WARNINGS AND PRECAUTIONS section of the medication's information.*

FDA Label Image

Image2.jpg (Image2)

This appears to be a laboratory measurement of the osmolality or concentration of a solution, given as 9 milliosmoles per liter. It was obtained using a calculation, the details of which are not provided. The second paragraph suggests that the solution being measured may have been adjusted using sodium bicarbonate or hydrochloric acid to achieve a desired pH. The rest of the text, which appears to be a sequence of numbers, is difficult to interpret without additional context.*

FDA Label Image

Label1.jpg (Label1)

The text describes a medical product called "Mannitol", which is administered intravenously using a single-dose fliptop vial. The product should be stored at a temperature of 20-25C and should only be administered through a sterile and intact seal. The user should warm the product to 80G if crystals form and agitate to dissolve. There is a warning about contraindication in severe renal impairment and a caution to use aseptic technique. The text also provides information about the manufacturer, expiry date, and lot number.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.